Yellow Fever Clinical Trial
Official title:
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril in Adults
VYF03 is a phase II, randomized, parallel-group prevention study with 2 arms, active-controlled (Stamaril), observer-blind, multi-center study to assess the non-inferiority of the immune response, in terms of seroconversion rates of the investigational vaccine candidate vYF to the licensed Stamaril, in adults aged 18 years up to 60 years in Europe (EU). The safety and immunogenicity profile of vYF in a cohort of Asian population of Chinese origin outside of China will also be described. The study will also assess the immunogenicity profiles and the safety profiles of vYF and Stamaril. Participants will be randomized in a 2:1 ratio to receive a single subcutaneous injection of either the vYF vaccine (380 participants in EU and 80 participants of Chinese origin in Asia) or Stamaril (190 participants in EU and 40 participants of Chinese origin in Asia), on Day 01. The duration of each participant's participation will be approximately 5 years.
The duration of each participant's participation will be approximately 5 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
| Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
| Recruiting |
NCT05447377 -
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
|
Phase 3 | |
| Completed |
NCT04267809 -
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection
|
Phase 2 | |
| Completed |
NCT01943305 -
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
|
Phase 2 | |
| Completed |
NCT02991495 -
Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)
|
Phase 4 | |
| Not yet recruiting |
NCT03725618 -
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
|
Phase 4 | |
| Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
| Completed |
NCT04059471 -
Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine
|
Phase 4 | |
| Completed |
NCT02572518 -
Immunity After Two Doses of Yellow Fever Vaccine
|
N/A | |
| Recruiting |
NCT00694655 -
Human Immune Responses to Yellow Fever Vaccination
|
Phase 4 | |
| Not yet recruiting |
NCT05332197 -
Booster Vaccine for Yellow Fever
|
Phase 3 | |
| Recruiting |
NCT05421611 -
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
|
Phase 3 | |
| Completed |
NCT03116802 -
Yellow Fever Vaccine on Statin/ Non Statin Subjects
|
Phase 2 | |
| Completed |
NCT02743455 -
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01426243 -
The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.
|
Phase 3 | |
| Completed |
NCT00982137 -
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
|
Phase 2 | |
| Active, not recruiting |
NCT04269265 -
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
|
Phase 1/Phase 2 | |
| Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A | |
| Completed |
NCT00995865 -
Trial of Yellow Fever Inactivated Vaccine
|
Phase 1 |